The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug development, attention is being turned to utilizing existing compounds approved for other indications as novel treatments in Parkinson's disease. Advances in rational and systemic drug repurposing have identified a number of drugs with potential benefits for Parkinson's disease pathology and offer a potentially quicker route to drug discovery. Here, we review the safety and potential efficacy of the most promising candidates repurposed as potential disease-modifying treatments for Parkinson's disease in the advanced stages of clinical testing.
Introduction
Parkinson's disease (PD) affects 6 million people worldwide. As it is an age-related neurodegenerative disease, and with longevity increasing in most Western countries, this figure is estimated to increase to around 10 million by 2030 [1] . The social impact on patients and their caregivers is immense, and the economic burden of PD is estimated at $US14.4 billion per year in the USA [2] , with increasing costs heavily weighted towards the more advanced features of the disease such as the development of cognitive impairment, nonmotor symptoms, gait abnormalities, and falls. Currently available symptomatic treatments for PD primarily focus on stimulation of dopaminergic signaling and can provide symptomatic relief for a limited time but have little effect on nonmotor symptoms, and none have been shown to affect the progressive pathological and clinical decline. Thus, alongside the need to develop more effective symptomatic therapies for PD, the greatest unmet need for patients, caregivers, and healthcare systems is the development of a disease-modifying treatment for PD.
The exact pathophysiological mechanisms underlying neurodegeneration in PD are not well understood. However, disruption of cell-autonomous processes involved in modulation of protein folding and aggregation, and noncell-autonomous processes involving mitochondrial function, oxidative stress, and inflammation, are all thought to be implicated, have provided possible targets for therapeutic intervention, and emphasize the need for a broader treatment approach [3, 4] .
Unfortunately, de novo drug discovery and development in PD is a lengthy, expensive, and risky process. The estimated cost of bringing a new drug to market, from conception and basic research through to clinical testing and regulatory approval, is approximately $US2.6 billion [5] and takes an average of 13-15 years [6] . Furthermore, it is estimated that only 10% of compounds make it through development to obtain approval by the European and/or the US regulatory authorities [7] . Figures released from the 2013 US FDA New Drug Summary report indicate that, despite a massive increase in research and development spending by pharmaceutical companies, the number of new molecular entities approved per year has remained static for the past decade. Therefore, it is perhaps unsurprising that drug companies are facing a paradigm shift (not necessarily voluntarily) in how drugs are discovered and developed [8] .
To address the high rates of attrition in drug development, pharmaceutical companies are increasingly exploring drug repurposing (also known as repositioning or reprofiling). This is the application of an existing drug to a new therapeutic use outside its original clinical indication [9] . Starting with a compound that already has extensive human pharmacokinetic and safety data allows pharmaceutical companies to bypass the long and costly preclinical stages required to advance a treatment to clinical trials and also opens up a drug development route to academic centers and not-for-profit organizations. Success rates utilizing drug repurposing have been reported to approach 30% [8] , a vast improvement on traditional routes of drug discovery, and this has led to numerous successes across many different areas, including cardiovascular disease, erectile dysfunction, cancer, and irritable bowel syndrome [9] . Amantadine, originally developed in the 1960 s as a prophylactic against several forms of influenza, has since been approved for the treatment of motor complications in PD. Although approval for amantadine as a treatment for PD followed several appropriately designed large clinical trials, the impetus for the investigation of amantadine as a treatment for PD was a single doctor-patient interaction [10] . Historically, serendipitous clinical observations have identified possible drugs for repurposing, but, recently, more rational, systemic approaches for identifying and screening potential drugs for repurposing are increasingly being utilized. Creating open access databases detailing information on the structure and mechanism of action of individual drugs increases the opportunities for identifying potential compounds for repurposing [11] . In addition, the creation of initiatives such as The National Centre for Advancing Translational Sciences (NCATS) Pharmaceutical Collection and the European Lead Factory has allowed the sharing of commercial compound libraries for collaborative public-private partnerships [12] . Similarly, novel computational approaches based on analyzing similarities between diseases, drugs, protein-protein interaction networks (PPINs) of genes, common adverse effects, and combinations of drug-target interactions are identifying more potential opportunities for repurposing [13, 14] . These methods have already been used to identify potential drugs for repurposing to address levodopa-induced dyskinesia, a common and often debilitating adverse effect of dopaminergic medication [15] . The development of novel symptomatic medications to treat PD is reviewed elsewhere [16] , and this review primarily addresses candidates evaluated for potential disease-modifying properties.
The creation of collaborative scientific networks to share and evaluate experimental data has also been valuable in the identification of candidate drugs for repurposing opportunities. In 2001, the National Institute of Neurological Disorders and Stroke (NINDS) organized the Committee to Identify Neuroprotective Agents for Parkinson's (CINAPS). This group comprised experts in PD, clinical trials, and clinical pharmacology and solicited suggestions from academia, industry, clinicians in practice, and the lay community to identify drugs that could be repurposed to slow disease progression in PD [17] . Among other criteria, drugs were evaluated in respect to availability of human safety data, evidence of blood-brain-barrier penetration, potential mechanism, and efficacy in preclinical models. In parallel, NINDS created the National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) program, a network of clinical sites where agents identified by CINAPS could be tested in 1-year futility trials. These trials were designed primarily to rapidly screen agents and identify compounds unlikely to have therapeutic benefit and to minimize the risk of taking potentially ineffective agents to larger, costly phase III trials [18] . Based on the CINAPS criteria, NET-PD investigators selected four compounds for further study, of which only one-creatine monohydrate-was not found to be futile, based on a modified futility analysis of two clinical trials. As a result, creatine was evaluated in a large, double-blind, randomized, controlled, long-term trial [Long-term Study 1 (LS-1)] involving 1741 patients with early PD, in 52 sites across North America [19] . Patients were randomized to receive creatine or placebo, and the primary outcome was the difference in clinical decline from baseline to 5 years, using a global statistical test that combined outcomes from a number of motor, nonmotor, and quality-of-life assessments. Although the study was designed to run for 5 years, it was terminated early for futility based on a planned interim analysis that detected no difference in clinical outcomes. Subsequently, another international committee of experts was assembled to form the Linked Clinical Trials Initiative (LCT). The aim was to offer a structured approach to identify and prioritize drugs for repurposing in PD to modify disease progression and accelerate into pilot clinical trials [20] . Following an extensive literature review process assessing criteria such as potential modes of action, safety, blood-brain-barrier penetration, and preclinical data, 26 candidate dossiers were drawn up. Of those, seven were chosen to progress into small "learning" clinical trials in patients with PD: exenatide, liraglutide, lixisenatide, deferiprone, deferasirox, simvastatin, and trehalose.
In parallel with improved methods of identifying potential drugs for repurposing, the development of novel unbiased screening platforms using cell-based assays, small organisms-based screening systems, and genetically engineered cell lines has helped to generate data required to advance potential candidates into clinical trials [21, 22] .
This review aims to highlight several repurposed drugs that are currently being evaluated in clinical trials for their potential disease-modifying effects in PD and to summarize the preclinical, epidemiological, and clinical evidence for each candidate and the potential further work required.
Drug Repurposing in Parkinson's Disease

Ambroxol
Mutations in the glucosylceramidase beta acid (GBA1) gene have been identified as the single largest risk factor for the development of idiopathic PD and as being present in up to 25% of patients with PD [23] . When present in the homozygous or compound heterozygous state, mutations in this gene cause Gaucher's disease (GD), whereas a single mutation is sufficient to increase the risk of PD. The mechanism underlying the GBA-mediated loss of function in PD is unclear but thought to be related to the activity of glucocerebrosidase (GCase), an enzyme encoded by GBA and involved in modulating lysosomal function and folding of α-synuclein. Significantly decreased GCase activity is found in the substantia nigra (SN) of both those with GBA-PD and those without GBA mutations [24, 25] ; in animal models, decreased GCase activity results in increased neocortical accumulation of α-synuclein and associated cognitive and motor deficits in vivo [26] . Encouragingly, these pathological and behavioral abnormalities can be halted by administration of viral gene-therapy-mediated overexpression of exogenous GCase [27] , though potential issues of distribution to affected tissues have led others to explore the use of small molecules to increase GCase activity. These molecules act as chaperones to increase GCase activity by facilitating the correct folding of mutant GCase molecules in the endoplasmic reticulum to aid their transport to lysosomes [23] . Ambroxol is a secretolytic agent licensed for use in the treatment of respiratory diseases and has been shown to act as a pharmacological chaperone [28] to enhance the activity of GCase in PD fibroblast lines [29, 30] , dopaminergic neurons from patients with PD and GBA1 mutations [31] , Drosophilia expressing GBA mutations [32] , transgenic mice overexpressing α-synuclein [33] , and non-human primates [34] . Encouragingly, the in vivo data indicated ambroxol could cross the blood-brain barrier and reduce the levels of α-synuclein and phosphorylated α-synuclein [33] .
A pilot initial study involving 12 patients with GD treated with ambroxol 150 mg/day for 6 months demonstrated good safety and tolerability [35] . A second open-label study involved administration of ambroxol in doses ranging from 375 to 1300 mg/day in five patients with GD for 48 months to assess safety and tolerability [36] . All doses demonstrated increased lymphocyte GCase activity, achieved a mean cerebrospinal fluid (CSF):serum ratio of 15.6% at the highest doses, and improvements in neurological deficits were observed across all patients. These two pilot trials in GD have provided tentative support for repurposing ambroxol in PD, and two trials are currently underway. An open-label trial involving 20 patients with PD (both with and without GBA mutations) will primarily evaluate the pharmacokinetics of ambroxol 1200 mg daily for 6 months (AiM-PD [NCT02941822]). In addition, a 52-week, phase II efficacy trial involving 75 patients with PD dementia randomized 1:1:1 to placebo or ambroxol low-dose (525 mg daily) or high-dose (1050 mg daily) will evaluate the change in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scale (NCT02914366). Despite the relatively quick advance of these molecular chaperones into clinical testing, uncertainty remains regarding the mechanism by which GBA mutations increase the risk for PD and influence disease progression. Furthermore, most current chaperones of GCase, including ambroxol, are in fact enzyme inhibitors, which may complicate potential future clinical development, as their chaperone activity must be balanced against the functional inhibition of the enzyme. Thus, novel molecules that do not cross-inhibit other glycosidases or inhibit GCase but still facilitate translocation to the lysosome are in development and may offer better efficacy [37] .
Isradipine
The selective vulnerability and degeneration of dopaminergic neurons of the SN pars compacta (SNc) in PD is thought to be related to the high energy demands of the spontaneous pacemaking properties of the neurons themselves [38] . This autonomous pacemaking is accompanied by slow oscillations of calcium influx triggered by the opening of plasma membrane Cav1 (Cav1.2, Cav1.3) Ca 2+ channels, which help meet intracellular bioenergetic needs by stimulating mitochondrial intermediary metabolism and oxidative phosphorylation. However, reliance on these channels increases with age. This continued generation of free radical species in combination with other stressors that occur in PD, such as misfolded α-synuclein or mutations in GBA1, can lead to increased mitochondrial oxidative stress and subsequent accelerated cell aging and death [39] . Although the Cav1 Ca 2+ channels participate in pacemaking, they are not essential for the SNc pacemaking function, so antagonizing these channels to limit the source of oxidative stress could potentially attenuate the degeneration of SNc dopamine neurons. Epidemiological data support this hypothesis and indicate that patients treated with centrally acting dihydropyridines (DHPs) (calcium channel blockers used for many years to treat hypertension and angina) may have a reduced risk of developing PD [40] [41] [42] , although this remains controversial [39] . It is thought that, of the various subtypes of Cav1 Ca 2+ channels, Cav1.3 channels, rather than the more common Cav1.2 channels, are most likely to mediate risk in PD. This is of relevance as most available DHPs preferentially inhibit Cav1.2 channels, but isradipine, licensed for the treatment of hypertension, has nearly similar affinity for Cav1.2 and Cav1.3 channels in membrane-binding assays, which, together with good brain bioavailability, has made it the most attractive candidate for repurposing [43] [44] [45] . Isradipine has subsequently been shown to protect dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-and 6-hydroxydopamine (6-OHDA)-induced toxicity in a dose-dependent manner by reverting dopaminergic neurons to a latent juvenile pacemaking mechanism independent of calcium [38, 46] .
In view of the encouraging data, an initial open-label, dose-escalation study of isradipine controlled-release 5-20 mg/day was conducted in patients (n = 31) with early PD to assess safety (STEADY-PD). It demonstrated acceptable tolerability at doses of ≤ 10 mg/day, with leg edema and dizziness causing intolerance at higher doses [47] . Subsequently, STEADY-PD-II, a randomized, double-blind, parallel-group trial, was undertaken in 99 subjects with early PD not requiring dopaminergic therapy to primarily assess a tolerable dosage of isradipine (at doses of 5, 10, and 20 mg), with secondary outcomes to detect any preliminary efficacy between the different doses after 52 weeks [48] . The primary outcome again confirmed tolerability was dose dependent, with isradipine 10 mg being the highest tolerated dose. Though there was no overall effect on blood pressure, the most common adverse effect was peripheral edema, which occurred in 34% of patients receiving isradipine 10 mg. Though the study was not powered for efficacy, data suggested a very modest advantage (~ 1 point in the total Unified Parkinson's Disease Rating Scale [UPDRS] score) in patients treated with isradipine 10 mg for 12 months [48] . A larger placebo-controlled phase III trial to assess the efficacy of isradipine 10 mg daily to slow progression of PD disability [STEADY-PD-III (NCT02168842)] is currently underway, with results expected in 2019. The trial involves 336 patients with early PD initially not requiring dopaminergic therapy, with the primary outcome designated as the change in total UPDRS score in the on-medication state. The results are eagerly anticipated, but a number of potential limitations exist. While the design will allow for determination of any long-term benefits of isradipine on motor complications and long-term PD medication use, if any potential advantages over placebo are detected, it may be difficult to exclude unexpected symptomatic effects (though these were minimal in the previous clinical trial). Furthermore, isradipine has been shown to have dose-dependent neuroprotective effects in animal models, with higher doses conferring better protection, and whether isradipine 10 mg/day will be sufficient in the current clinical trial is unclear. Emerging candidates from preclinical studies, including novel, highly selective Cav1.3 antagonists, may offer more promising results in the future without producing the adverse effects that accompany general antagonism of L-type calcium channels [49] .
Inosine
Growing data from prospective studies [50] [51] [52] [53] and Mendelian randomization studies [54, 55] indicate individuals with elevated levels of serum urate, an antioxidant, have a decreased risk of developing PD, though the association appears weaker and less consistent in women [56] [57] [58] [59] . Furthermore, elevated urate levels in serum and CSF from patients with PD are associated with a reduced rate of disease progression [60] . In addition, pretreatment of rodents to elevate urate levels conferred protection against dopaminergic cell death induced by MPTP, 6-OHDA, and rotenone in toxin-based models of PD. These effects were thought to occur via modulation of Akt-GSK-3B signaling and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein, a master regulator of the oxidative stress response [61] [62] [63] .
In view of the data supporting a neuroprotective role for urate in the disease pathogenesis of PD, clinical studies have been undertaken to evaluate the effects of manipulating urate levels using its precursor inosine, a freely available dietary supplement taken by athletes to improve aerobic performance. In SURE-PD, a randomized, double-blind, placebocontrolled, dose-ranging trial of inosine, 75 patients with early PD not yet requiring any medication were randomized 1:1:1 to receive either placebo or inosine titrated to produce mild serum urate elevation (6.1-7.0 mg/dl) or moderate urate elevation (7.1-8.0 mg/dl) for 25 months, with the primary endpoint being safety, tolerability, and ability to raise urate levels in serum and CSF [64] . Inosine was well-tolerated, though three patients developed symptomatic nephrolithiasis. It was associated with a favorable rate of progression based on changes in UPDRS scores over 24 months, whichafter adjustment for baseline differences-amounted to ~ 1 point per year on the total UPDRS scale. Although the trial data were not powered to determine efficacy, there was no difference between groups in the time to requiring dopaminergic therapy, and few patients reached the 2-year analysis timepoint. Furthermore, elevated serum urate has also been shown to increase the risk of hypertension, coronary heart disease, gout, and stroke over the longer term. Although the number of patients with PD treated with inosine thus far is small, these side effects are potentially problematic for older patients with PD, potentially limiting its utility [65] . However, a recently reported trial of ten patients of Asian origin with PD treated with inosine to elevate urate levels to 6.0-8.0 mg/dl reported no adverse effects after 1 year of treatment [66] . SURE-PD3 (NCT02642393) is a multicentre, randomized, double-blind, placebo-controlled trial currently underway to evaluate the effects of elevating serum urate to 7.1-8.0 mg/dl using inosine in patients with early PD. The trial involves 240 patients, and the primary outcome is the rate of clinical decline as assessed by change in Movement Disorder Society-sponsored revision of the UPDRS (MDS-UPDRS) part 3 over 24 months, with results expected in 2020.
Ursodeoxycholic Acid (UDCA)
Given the importance of mitochondrial function in the pathogenesis of sporadic and familial PD [67] , researchers used a novel high-throughput assay to screen 2000 compounds from the Microsource Compound library to assess their rescue effects on mitochondrial function in parkin (PARK2)-mutant fibroblasts to identify potential compounds for repurposing in PD [21] . Two compounds were identified: ursocholanic acid and the related compound dehydroursolic acid lactone (11, 12) . As neither were licensed drugs and little clinical safety data were available, researchers then evaluated the effects of the closely related ursodeoxycholic acid (UDCA). UDCA has been used as treatment for cholestatic liver disease for a number of years and is a first-line treatment for primary biliary cirrhosis. UDCA was subsequently shown to rescue mitochondrial function in both parkin-and LRRK2-mutant fibroblasts, possibly via increased phosphorylation of Akt. UDCA has also demonstrated potent anti-apoptotic, antioxidant, and anti-inflammatory effects in hepatocellular models [68, 69] and has demonstrated that these effects extend to several neurodegenerative models of disease, including PD. UDCA has been shown to be able to partially rescue a PD model of Caenorhabditis elegans; increase survival of nigral transplanted tissue in rodents, resulting in improved behavioral function [70, 71] ; and attenuate dopaminergic cell loss in vivo induced by rotenone [72] . These findings were thought to be related to beneficial effects on mitochondrial and inflammatory pathways and regulation of the phosphoinositide 3 kinase (PI3 K)-Akt pathway [73] .
In terms of potential repurposing for PD, data from a clinical trial of UDCA in 18 patients with amyotrophic lateral sclerosis (ALS) treated for 4 weeks at doses ranging from 15 to 50 mg/kg/day indicated a CSF:serum ratio of approximately 0.6% at the highest dose of 50 mg/kg/day [74] . Although the trial reported good tolerability, the current licensed dose of UDCA is 10-15 mg/kg/day, with an increased risk of hepatocellular carcinoma and liver toxicity reported at doses of 28 mg/kg/day, so further long-term PDspecific data regarding safety, tolerability, and CSF studies are needed [75] . A phase I open-label trial evaluating the safety and pharmacokinetics of UDCA 50 mg/kg/day in 20 patients with PD is currently underway (NCT02967250), and a trial of UDCA in patients with PD to evaluate the effect of on disease progression has received funding and is due to start imminently. PD-specific pharmacokinetic data regarding UDCA are awaited; however, in view of potential issues regarding incomplete absorption of UDCA from the gut, interest is growing in the UDCA derivative tauroursodeoxycholic acid (TUDCA) (not currently approved for use). As TUDCA crosses the blood-brain barrier, has demonstrated better oral bioavailability and neuroprotection against MPTP-and α-synuclein-induced stress in vitro and in vivo [71, [76] [77] [78] , and has indicated potential benefits in a small randomized controlled trial in 34 patients with ALS [79] , it may offer better potential.
Deferiprone
Growing evidence suggests dysregulation of cerebral iron homeostasis occurs in several neurodegenerative disorders, including PD, and thus represents a novel therapeutic target. Although iron accumulates in the brain as part of normal aging, post-mortem, magnetic resonance imaging (MRI), and transcranial ultrasonography imaging studies of patients with sporadic PD have indicated increased regional iron accumulation in the SN, [80] [81] [82] . Other studies suggest the degree of nigral iron deposition may relate to motor severity [83] . Further studies have confirmed that excess iron deposits in individual dopaminergic neurons in the SNc are associated with neuromelanin granules, Lewy bodies, and activated microglia [84] [85] [86] . This excess labile iron can influence neurodegeneration by generating reactive oxygen species, activating microglia and pro-inflammatory pathways, promoting α-synuclein misfolding and aggregation, and triggering cell death by iron-dependent pathways, termed "ferroptosis" [87] [88] [89] . Thus, removal of excess cerebral iron in PD may be a useful strategy [90] . Current studies regarding iron chelation in PD have focused on deferiprone, licensed as a treatment for thalassemia syndromes and cardiac iron-overload diseases at doses of 75-100 mg/ kg/day. Unlike other iron chelators, deferiprone can redistribute excess intracellular iron to the extracellular apotransferrin to avoid severe systemic iron losses and can cross the blood-brain-barrier in rodent models [91] . Furthermore, deferiprone has been shown to remove excess labile iron and to attenuate dopaminergic neuronal loss in MPTP mouse models [92] and to inhibit dopaminergic neuron necrosis, ferric ion accumulation, and microglial proliferation and reduce the hyperechogenic area of the SN in 6-OHDA rodent models [93, 94] . In a transgenic mouse model overexpressing A53T, deferiprone significantly improved impairments in the rotarod task and the novel object recognition test (though this was not accompanied by changes in α-synuclein aggregation) [95] .
Three clinical trials of deferiprone in PD have been conducted. An initial pilot double-blind, randomized controlled trial (FAIRPARK) with a delayed-start design evaluated 40 patients with early-stage PD randomly assigned to receive oral deferiprone 30 mg/kg/day or placebo for 12 months, using the change in iron overload in the SN (as measured by the T2* MRI sequences) as the primary outcome [92] . The results indicated a 12-month course of deferiprone significantly reduced foci of accumulated iron in the SN of patients with PD without detectable changes in other brain areas or systemic levels. In addition, the early start (deferipronetreated) group showed a reduction in the UPDRS motor subscale (− 2.3 ± 0.6) compared with the delayed-start group (+ 1.0 ± 0.7), which was sustained at 12 months-though improvements waned after 18 months of continuous treatment [92] . Further post hoc analysis indicated patients with PD with lower caeruloplasmin ferroxidase activity appeared to respond better to chelation therapy [96] . In a recently completed phase II double-blind placebo-controlled study (Deferiprone PD), 22 patients with early-stage PD were randomized to receive deferiprone 20 or 30 mg/kg/day or placebo for 6 months, with the primary outcome being changes in regional brain mineralization as assessed with T2* MRI [97] . Deferiprone treatment led to reduced dentate and caudate nucleus iron content compared with placebo, with three patients showing alterations in the T2* MRI values for SNc. In addition, patients receiving deferiprone 30 mg/kg showed a trend (albeit not statistically significant) for improvement in motor-UPDRS scores and quality of life. Deferiprone was generally well-tolerated, but five patients across both studies developed neutropenia, necessitating early drug withdrawal.
These studies have provided support for the repurposing of deferiprone in PD, though questions remain regarding the iron chelator of choice. Although deferiprone has been used in the majority of neurodegenerative trials, desferrioxamine has been similarly shown to reduce excess brain iron deposits in patients with aceruloplasminemia [98] and prevented aggregation of α-synuclein and reduced oxidative stress in dopaminergic neurons, though it is unable to cross the blood-brain barrier [99] . This may suggest the ability to cross the blood-brain barrier may not be necessary for brain iron removal and that these two agents have different pools of chelation, potentially indicating that combination therapy (which has proved efficacious in the treatment of other iron storage disorders) may be more beneficial [100] . Nevertheless, whether excessive iron represents a cause or consequence of dopaminergic neuronal cell death is uncertain, but the short-term efficacy results are highly encouraging. It remains to be seen whether the observed clinical benefits in patients with PD were a result of iron chelation alone or via permissive effects of chelation on dopaminergic treatments, but other preliminary successes with iron chelation in neurodegenerative diseases such as Friedreich's Ataxia [101] provide further support for its potential, and further phase II/III trials are now underway. A randomized, double-blind, placebo-controlled trial involving 338 patients with treatmentnaïve PD is evaluating the use of deferiprone 30 mg/kg/day on the total MDS-UPDRS score at 36 weeks [FAIRPARK-II (NCT02655315)], and a randomized, double-blind trial of deferiprone in 140 patients with PD is assessing doses of deferiprone 600-2400 mg/day on the MDS-UPDRS part 3 over 9 months (SKY, NCT02728843).
Exenatide
A meta-analysis of longitudinal cohort studies identified type 2 diabetes mellitus (T2DM) as a modest risk factor for developing PD (relative risk [RR] 1.32) [102, 103] , though the heterogeneity of studies made it difficult to draw firm conclusions. However, the presence of coexisting T2DM seems to influence disease progression, as patients with coexisting T2DM develop earlier cognitive impairment, gait, and balance issues than patients with PD without T2DM, even after excluding those with diabetes-related complications such as peripheral neuropathy and vascular complications [104, 105] . One hypothesis linking PD and T2DM is disruption of physiological insulin signaling. Neurons are especially vulnerable to stress in the presence of dysfunctional insulin signaling [106] , whereas, conversely, disrupted insulin signaling leads to accumulation of oxidative stress and PD pathology [107, 108] , thus linking PD and insulin signaling in a complicated positive feedback system [109] . Indeed, evidence of disrupted insulin signaling or "brain insulin resistance" has been demonstrated in post-mortem tissue from patients with PD without coexisting peripheral insulin resistance or T2DM [110, 111] . Whether these changes are related to the causes of, or are simply consequences of, neurodegeneration is unclear, but considerable data now relate central insulin resistance to neuronal survival pathways [112] . Rather than simply administering exogenous insulin to restore these dysfunctional pathways (which comes with risks inherent to administering insulin to nondiabetics), an indirect route to address this aspect of PD pathology is to explore compounds that influence insulin release.
Exenatide is a synthetic glucagon-like peptide-1 (GLP-1) agonist licensed for the treatment of T2DM as an agent that promotes insulin secretion [113] . Neurotrophic properties of GLP-1 receptor agonists were first identified in 2002 [114] . Since then, there have been multiple reports of beneficial effects from GLP-1 receptor agonists in a wide range of toxin-based models of PD, including the MPTP, 6-OHDA, and lipopolysaccharide (LPS) models [115, 116] , and two α-synuclein animal models [117] . These have allowed investigations into the potential mechanisms of action of GLP-1 agonists, which appear to have multiple effects relevant to the neurodegenerative processes of PD. Some laboratories have shown that GLP-1 receptor stimulation exerts antiinflammatory effects [115] , most convincingly associated with prevention of microglial-mediated conversion of astrocytes to an A1 neurotoxic phenotype [117] , which was associated with protection against loss of dopaminergic neurons and behavioral deficits in the α-synuclein preformed fibril (α-syn PFF) mouse model of PD. However, others have indicated these anti-inflammatory properties may not necessarily be relevant to all of their therapeutic effects [118] . Furthermore, neuroprotective and neurorestorative effects have been seen in association with beneficial effects on mitochondrial function [119] , synaptic plasticity [114, 120] , and stimulation of neurogenesis [121] , and through enhancing the actions of brain-derived neurotrophic factor (BDNF) [122] . It is likely that all of these actions are inter-related, possibly through an effect of GLP-1 receptor stimulation on insulin resistance and downstream Akt signaling [123] .
Two trials of exenatide have been conducted in patients with PD. The first was a small, parallel-arm, open-label trial involving 44 patients with moderate-stage PD randomized either to receive exenatide 10 μg twice daily (Byetta) for 12 months or to act as controls. Patients were approximately 60 years old, had a mean duration of PD of about 10 years, and were using a mean 975 mg L-dopa equivalent. The primary outcome was change from baseline in MDS-UPDRS part 3 at 14 months (2 months after exenatide withdrawal) measured in the off-medication state after an overnight withdrawal from PD medication. The evaluation was performed via video by assessors blinded to treatment allocation. At 14 months, the group randomized to exenatide twice daily had a 1.7-point improvement, whereas the group maintained on conventional medication alone had deteriorated by 2.8 points. In addition, among the secondary outcomes, patients receiving exenatide had improved by 2.8 points on the Mattis Dementia Rating Scale (MADRS-2) at 14 months, whereas the control group had deteriorated by 3.5 points [124] . After extended follow-up in the absence of any further treatment with exenatide, at 2 years, exenatide-treated patients maintained an advantage of 5.6 points and 5.3 points over the control group on the MDS-UPDRS part 3 and MADRS-2, respectively [125] . The drug was well-tolerated in this patient group, though the well-known side effects of weight loss, nausea, and dysgeusia were more common in the exenatide group and contributed to the early withdrawal of exenatide in two patients. Although encouraging, the openlabel nature of the trial meant that these results may have been influenced by long-lasting placebo effects and could not be taken as proof of efficacy. A subsequent double-blind placebo-controlled trial involving 60 patients was recently reported [126] . In comparison with the previous trial, these patients had shorter disease duration (mean 6.4 years) and were receiving approximately levodopa 800 mg equivalents. Patients were randomly assigned to exenatide 2 mg once weekly (Bydureon; chosen because of its lower adverseeffect profile vs. the twice-daily formulation) or placebo for 48 weeks, after which there was a 12-week washout period before comparing scores on the MDS-UPDRS part 3 (again assessed in the off-medication state). The exenatide-treated group had a statistically significant advantage over placebo of 4.3 points [95% confidence interval (CI) − 7.1 to − 1.6; p = 0.0026] and 3.5 points (95% CI − 6.7 to − 0.3; p = 0.0318) at 48 and 60 weeks, respectively. There were no other statistically significant differences between the two groups on other outcome measures, although a post hoc analysis indicated potential beneficial effects on mood/ depression in the exenatide group [127] , and the direction of effect favored exenatide for almost all measures.
These results, while encouraging, must still be interpreted with caution and should be regarded as "proof of concept" rather than of efficacy. Both trials were small single-center studies, so the baseline severity of patients in the exenatide and placebo groups differed despite randomization. Also, although exenatide was well-tolerated and safe in normoglycemic individuals, a recognized side effect of exenatide and other GLP-1 agonists is weight loss, which can have detrimental effects in patients with advanced PD. Furthermore, despite the existing laboratory data, it is yet to be convincingly demonstrated in people with PD whether any clinical effects relate to symptomatic effects on the dopamine system or disease-modifying actions on the underlying pathophysiological processes of PD. Careful consideration must be given to trial design to enable clarification of these possibilities [4] , and a larger, multicentre phase III study is due to start soon.
Although exenatide was the first in class of GLP-1 receptor agonists, four other GLP-1 agonists have since been licensed for the treatment of T2DM: lixisenatide (an incretin mimetic like exenatide, based on the structure of exendin-4), liraglutide, dulaglutide, and albiglutide (based on the structure of human GLP-1 and termed GLP-1 analogues). In PD models, data exist for liraglutide and lixisenatide that have similarly demonstrated neuroprotective effects in animaltoxin models of PD, preventing MPTP-, 6-OHDA-, and rotenone-induced dopaminergic cell loss and motor impairments associated with reduction in pro-apoptotic signaling, pro-inflammatory cytokine production, and promotion of neurotrophic factors, such as glial cell-derived neurotrophic factor (GDNF) [128] [129] [130] [131] . Although no clinical data from patients with PD are available for other GLP-1 agonists, data from a double-blind randomized controlled trial assessing the effects of liraglutide on cerebral amyloid deposits in patients with AD (which have similar links with dysfunctional insulin signaling) have been reported. This study indicated liraglutide treatment halted decline of cerebral glucose metabolism compared with controls, suggesting an ability to stabilize energy metabolism in areas of the brain that have been shown to correlate with cognitive decline in patients with AD [132] . In addition, data from diabetes trials suggest varying efficacy, tolerability, and pharmacokinetics between agents within the GLP-1 agonist class [133] ; thus, it is reasonable to assume similarly varying efficacy in models of neurodegeneration. Few studies have compared the relative neuroprotective effects of GLP-1 agonists, though one study suggested greater efficacy of liraglutide in comparison with exenatide in an MPTP model of PD (though differences in dosing regimens were not addressed) [131] . Clinical data similarly suggest varying degrees of central nervous system (CNS) penetrance between exenatide and liraglutide [126, 134] , though the relevance of this is uncertain. In summary, preliminary evidence suggests that GLP-1 agonists may represent a potential new treatment for PD, with encouraging in vitro and in vivo studies hinting at possible mechanisms of action, though questions remain regarding the nature of effects seen, dosing, tolerability, and long-term outcomes. Several clinical trials of GLP-1 agonists are underway, which reflects the promise of this class of drugs in PD. A small open-label imaging study will use functional MRI to evaluate imaging changes in 20 patients receiving exenatide 2 mg once weekly for 12 months (NCT03456687); a single-center, double-blind, placebo-controlled efficacy study involving 57 patients with early-stage PD will evaluate the effects of liraglutide 1.2 or 1.8 mg over 14 months on MDS-UPDRS part 3, nonmotor symptom scale, and MADRS-2 scores (NCT02953665); and a multicenter, randomized, placebo-controlled, double-blind phase II trial will evaluate the effects of 12 months of treatment with lixisenatide 20 μg/ day in 158 patients with early-stage PD, assessing changes in the MDS-UPDRS part 3 scores (NCT03439943).
Nilotinib
Nilotinib is a second-generation brain penetrant Abelson (c-Abl) tyrosine kinase inhibitor licensed for the treatment of chronic myeloid leukemia (CML) in doses ranging from 300 to 1200 mg/day. Accumulating evidence from animal and genome-based studies suggests c-Abl activation plays a role in the pathogenesis of PD and other synucleinopathies. Elevated levels of activated (phosphorylated) c-Abl have been found in the SN in post-mortem studies of patients with PD [135, 136] , whereas activation of c-Abl in mice induces neurodegeneration in the hippocampal and striatal brain areas [137] . Further work has demonstrated that c-Abl phosphorylation occurs as a result of mitochondrial dysfunction and oxidative stress [138] , can promote accumulation of α-synuclein through effects on autophagy mechanisms [137] , and can promote phosphorylation of parkin, causing inhibition of its ubiquitin E3 ligase activity, inducing mitochondrial dysfunction and dopaminergic neuronal death [136] . Taken together, there is ample evidence that c-Abl may be a promising therapeutic target in PD. Given the relatively better CNS penetration of nilotinib over other c-Abl inhibitors, this has garnered the most data in PD studies. Indeed, in preclinical models of PD, nilotinib has been shown to cross the blood-brain barrier and reduce c-Abl activity, ameliorating autophagic clearance of α-synuclein in transgenic and lentiviral gene-transfer models [137] . Importantly for potential drug repurposing, these effects were seen at doses far lower (1-10 mg/kg/day) than those used to treat CML. Furthermore, nilotinib prevented dopaminergic cell loss and motor impairments induced by MPTP in mice, which were associated with inhibition of parkin phosphorylation and reduced accumulation of parkin substrate PARIS, thus hinting at another potential mechanism of action [139, 140] . Based on these preclinical data, a small, open-label proof-of-concept study was recently conducted to evaluate the safety and tolerability of nilotinib in 12 patients with PD dementia or dementia with Lewy bodies followed-up for 24 weeks, followed by a final assessment 12 weeks later [141] . Although neuroprotective effects were seen at low doses of nilotinib in animal models of PD, the choice of dose for the clinical study was necessarily the lowest doses commercially available: 150-300 mg. The authors reported that nilotinib was well-tolerated, though one patient receiving 300 mg was diagnosed with myocardial infarction and two had transient QTc prolongations. There was also evidence of CNS penetration, with a nilotinib CSF:plasma ratio of 12 and 15% with 300 and 150 mg, respectively. Exploratory analysis of clinical outcomes revealed an improvement of 3.4 and 3.6 points in the groups receiving 150 and 300 mg at 24 weeks, which reverted to baseline at the 36-week followup. The numerous methodological limitations of the study mean that these findings should be interpreted with caution [142] . Although the authors commented that the one patient who experienced a serious cardiac adverse event should be interpreted as a failed screening procedure, known side effects of nilotinib at doses used to treat CML include cardiac conduction abnormalities and sudden cardiac events due to unwanted off-target nonselective tyrosine kinase inhibition, so claims of tolerability should be interpreted with caution. Also given the lack of a placebo control and blinding of the assessors, combined with the known magnitude of placebo effects that can be observed over time periods similar to those in the study, it is impossible to conclude any effects on efficacy. In addition, despite the changes in dopamine metabolites and markers of neuronal damage the authors reported in the CSF, none of the markers used are validated as biomarkers in PD; they can also vary greatly between patients and track poorly with disease stage and progression. Questions remain as to the optimum dose of nilotinib, its brain penetrance, assessments of cardiovascular toxicity, and evaluation of unwanted off-target effects, but the preclinical data and preliminary clinical study results have opened up a new molecular pathway previously untargeted in clinical trials and should be explored further. As a result, two fully randomized, double-blind, placebo-controlled trials are underway: NILO-PD (NCT03205488) will assess the safety and tolerability of oral nilotinib 150-300 mg/day for 12 months in 135 patients with PD, and PD-nilotinib (NCT02954978) will involve 75 patients with PD assigned to either placebo or nilotinib 150 or 300 mg for 12 months to further evaluate safety and tolerability and explore efficacy. Emerging research into more potent, selective c-Abl inhibitors is already showing promise in preclinical models of PD [143] .
Simvastatin
Statins, as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), are widely prescribed for their ability to lower cholesterol and reduce cardiovascular risk. Studies have shown statins can also modulate a number of biological processes known to be relevant to the pathogenesis of neurodegenerative diseases, including PD, including attenuation of α-synuclein aggregation, inhibition of oxidative stress and pro-inflammatory pathways, stimulation of nitric oxide synthase, and promotion of neurotrophic factors [144, 145] .
Pretreatment with simvastatin preserved dopaminergic cells and motor behavior in rodents treated with 6-OHDA, possibly via activation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase/p38 mitogen-activated protein kinase (MAPK) pathway promoting antioxidant protein expression or via modulation of N-methyl-d-aspartate Oral NAC prevention of DA cell death and motor abnormalities in MPTP and transgenic mice overexpressing α-synuclein and hESC-derived midbrain dopamine neurons treated with rotenone [158] [159] [160] . IV NAC raised brain glutathione levels in patients with PD [161] not replicated by oral administration [162] (NMDA) receptor and pro-inflammatory cytokine expression [146] [147] [148] . Similarly, in MPTP models, pretreatment with simvastatin at doses equivalent to those licensed in humans suppressed activation of nuclear factor (NF)-κB, protected dopaminergic neurons, and improved motor function [149, 150] . Unfortunately, despite encouraging preclinical studies, epidemiological data regarding the association between statin use and the risk of PD are unclear and confounded by the use of statins themselves and their relationship with cholesterol, meaning studies have suggested statins are associated with an increased risk, decreased risk, or no risk. The most recent meta-analysis concluded a modest protective effect of statins that disappeared when adjusted for cholesterol level [151] . However, based on its promising biochemical, and pharmacological safety and efficacy profile [20] and its ability to cross the blood-brain barrier, simvastatin 80 mg daily is currently being evaluated in a phase II double-blind, randomized, controlled, multicentre trial involving 235 patients with moderate-stage PD (Hoehn and Yahr < 3.0). Patients will be followed for 24 months, with a final assessment at 26 months after drug withdrawal, with the primary outcome specified as change in MDS-UPDRS part 3 (OFF) score.
Conclusion
As well as the drugs discussed here, numerous other candidates are being assessed for potential repurposing in PD with preliminary human trials in planning (Table 1) . Despite the potential advantages offered by drug repurposing, as a strategy it offers unique challenges, including the unavoidable need for expensive and risky clinical trials to demonstrate safety and efficacy in a new population while the limited patent protection often means a lack of commercial interest or incentive for further investment [147] . In addition, as the failed clinical trials of repurposed drugs pioglitazone, creatine, and coenzyme Q10 in PD have shown, despite promising preclinical evidence, repurposing available drugs for PD is not guaranteed for success. It is outside the scope of this article to explore the various aspects of why these trials failed, but it likely relates to our still limited understanding of PD pathogenic mechanisms, inadequate animal models in which to screen interventions that recapitulate human PD, the heterogeneity of PD, and the lack of any biomarkers with which to monitor disease progression and response to treatment (see Lang and Espay [152] for review). Furthermore, given the clinical and pathological heterogeneity of PD, it is unclear whether utilizing cohorts with genetic abnormalities and directing treatments at correcting those defects, as per the ambroxol trials, or using a broader approach to detect changes in heterogeneous population will prove fruitful. Still further questions remain regarding the "single-target" approach. As PD has multifactorial etiologies, it might be more appropriate to offer combinations of compounds that target different but potentially complementary biological mechanisms. Also, as the described examples attest, many of the drugs currently in clinical testing have various "dirty" off-target or unintended adverse effects that may limit their maximal therapeutic potential. Even if these trials fail to report positive outcomes, they may indicate a signal of effect that may potentially be optimized by molecules specifically designed to engage similar targets with improved brain penetration/ligand binding/selectivity [153] . Despite these challenges, appropriate drug repurposing remains an appealing method for accelerating muchneeded treatments in PD, offering established safety data and substantially reducing the costs of clinical development. In addition, advances in computational models and novel high-throughput screening have identified numerous potential candidates for potential use in PD and, in parallel, new funding opportunities for small pilot learning trials have increased opportunities for collaboration between academia and the pharmaceutical industry. We are cautiously optimistic that a therapy that can alter the course of disease progression in PD may be on the horizon.
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